Drugs / LY4052031
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06465069 | Jul 2024 → May 2027 expected | cervical cancer, esophageal cancer, head and neck squamous cell carcinoma, malignant pancreatic neoplasm +7 | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY4052031 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06465069 ↗ |
| Modality | Other / unclassified | “This study evaluates an antibody-drug conjugate that binds to the protein nectin-4, which is expressed on certain cancer cells, delivering the drug to the cancer.” NCT06465069 ↗ |
| Route | Intravenous | “Escalating doses of LY4052031 administered intravenously (IV).” NCT06465069 ↗ |